Released Jan 30, 2023, after the close
10-K filed Jan 30, 2023, 91 days after period end · 0001654954-23-001018
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.64M$4.64M derived−17.1% vs Q4 2021−2.8% vs Q3 2022
Net Income$173.38K$173.38K derivedN/M vs Q4 2021−39.8% vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$1,108,645−26.0%
Operating Incomederived$168,962N/M
Operating Cash Flowderived$260,091−72.9%
Free Cash Flowderived$247,954−74.2%
Margins · derived
Gross margin23.9%−2.9 pt vs Q4 2021
Operating margin3.6%+89.4 pt vs Q4 2021
Net margin3.7%+90.8 pt vs Q4 2021
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $4.64M | $5.60M | $5.03M | $4.82M |
| Net Income | $173.38K | -$4.87M | $144.35K | $477.60K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR